Oncology Breakthroughs: Lung, Breast, Ovarian & Emerging Trials

1 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
Aprea begins dosing HPV+ head and neck cancer patients with WEE1 inhibitor APR-1051. Darovasertib earns FDA Breakthrough status in uveal melanoma. Enhertu gains EU approval for HER2-low breast cancer, while Imfinzi-based regimens advance in lung cancer. BeiGene halts ociperlimab but progresses TEVIMBRA. Positive safety data reported for VCN-01 in pancreatic cancer and SON-1010 in ovarian cancer. Tovecimig and relacorilant meet key endpoints in biliary and ovarian cancers. Mabwell advances B7-H3 ADCs, and Astellas partners with JFCR to speed early-stage R&D in treatment-resistant cancers.
Category
Oncology
Be the first to comment

Up Next